Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data
| Autor: | Blake Cady, Samer Sbayi, James E. Gervasoni |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Lymphovascular invasion medicine.medical_treatment law.invention Randomized controlled trial Surgical oncology law Neoplasms medicine Humans Lymph node Survival analysis Neoplasm Staging Randomized Controlled Trials as Topic business.industry Cancer medicine.disease Prognosis Primary tumor Survival Analysis Surgery medicine.anatomical_structure Oncology Lymphatic Metastasis Lymph Node Excision Lymphadenectomy Radiology business |
| Zdroj: | Annals of surgical oncology. 14(9) |
| ISSN: | 1068-9265 |
| Popis: | The role of lymphadenectomy as an adjunct of standard excision for treatment of cancer is highly debated and controversial. Standard practice for treatment of solid tumors is resection with regional lymphadenectomy. This surgical concept assumes that cancers grow and spread in an orderly manner, from primary cancer to regional lymph nodes and finally to vital organs. We reviewed randomized trials, published a description of lymphatic anatomy and physiology, and presented data that disputed the role of lymphadenectomy as standard practice. The present review updates the literature and reiterates the concept that lymphadenectomy does not increase survival in the surgical treatment of solid tumors. We reviewed the English-language literature (Medline) for prospective randomized trials and nonrandomized reports, as well as retrospective studies addressing the role of lymphadenectomy in cancers of the esophagus, lung, stomach, pancreas, breast, and skin (melanoma) reported between 2000 and 2006. This extensive review demonstrates that there are few prospective randomized trials assessing patient survival with solid tumors that contrast resection with or without lymphadenectomy. However, there was at least one, and for some cancers more than one, prospective randomized trial for each organ site studied, and the data demonstrate no statistically significant difference in overall survival of patients treated with or without lymphadenectomy. Most nonrandomized and retrospective studies, with a few exceptions, support the conclusions of randomized trials; lymphadenectomy does not improve overall survival in solid tumors. Overall survival is primarily a function of the biological nature of the primary tumor, as evidenced by lymphovascular invasion, lymph node involvement, and other prognostic features. This extensive literature review of recent reports indicates that lymphadenectomy does not improve overall survival. Lymph node resection should be conceived in terms of staging, prognosis, and regional control only. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink